Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
ABBV-744 (ABBV744) is a novel, potent and highly BDII-selective BET bromodomain inhibitor with anticancer and anti-inflammatory activity. As a BDII-selective BET bromodomain inhibitor, it is under investigation for the treatment of AML and metastic castration-resistant prostate cancer. It also has the potential to be used in the treatment of inflammatory diseases and AIDS.
Targets |
|
|
---|---|---|
ln Vitro |
KLK2 and MYC gene expression is downregulated by ABBV-744 (90 nM; 0~24 h; LNCaP cells) [1]. Senescence is induced by ABBV-744 (90 nM; 0~72 h) on LNCaP cells, which causes cell cycle arrest in the G1 phase [1].
|
|
ln Vivo |
In comparison to ABBV-075 [1], ABBV-744 (4.7 mg/kg; interfacial gavage; 28 days) shown comparable or superior anti-tumor effectiveness and retarded the formation of tumors. /kg; 14) has strong anti-tumor properties. By 20%, ABBV-744 (30 mg/kg) suppresses interference [1].
|
|
Cell Assay |
Western Blot Analysis[1]
Cell Types: LNCaP cells Tested Concentrations: 90 nM Incubation Duration: 0~24 hrs (hours) Experimental Results: Downregulated the expression of KLK2 and MYC genes. Cell Cycle Analysis[1] Cell Types: LNCaP cells Tested Concentrations: 90 nM Incubation Duration: 0~72 hrs (hours) Experimental Results: Induced cell cycle arrest in G1 followed by senescence. |
|
Animal Protocol |
Animal/Disease Models: Mouse
Doses: 4.7 mg/kg (pharmacokinetic/PK/PK analysis) Dosing: po (oral gavage); 28-day Experimental Results: compared with ABBV-075, caused tumor growth delay and demonstrated the same or better anti- tumor activity. Animal/Disease Models: SD (SD (Sprague-Dawley)) rat Doses: 30 mg/kg (pharmacokinetic/PK/PK analysis) Dosing time: 14 days Experimental Results: Produced significant anti-tumor activity. |
|
References |
[1]. Faivre EJ, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature. 2020;578(7794):306-310.
|
Molecular Formula |
C28H30FN3O4
|
---|---|
Molecular Weight |
491.5539
|
CAS # |
2138861-99-9
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C(C(N1)=CC(C(C2=CC(C(C)(O)C)=CC=C2OC3=C(C)C=C(F)C=C3C)=CN4C)=C1C4=O)NCC
|
InChi Key |
OEDSFMUSNZDJFD-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C28H30FN3O4/c1-7-30-26(33)22-13-20-21(14-32(6)27(34)24(20)31-22)19-12-17(28(4,5)35)8-9-23(19)36-25-15(2)10-18(29)11-16(25)3/h8-14,31,35H,7H2,1-6H3,(H,30,33)
|
Chemical Name |
N-ethyl-4-(2-(4-fluoro-2,6-dimethylphenoxy)-5-(2-hydroxypropan-2-yl)phenyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide
|
Synonyms |
ABBV744; ABBV 744; ABBV-744.
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~203.44 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.09 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2 mg/mL (4.07 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2 mg/mL (4.07 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: 2.5 mg/mL (5.09 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0344 mL | 10.1719 mL | 20.3438 mL | |
5 mM | 0.4069 mL | 2.0344 mL | 4.0688 mL | |
10 mM | 0.2034 mL | 1.0172 mL | 2.0344 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.